Arrowhead Research Corporation (ARWR) Receives Patent Allowance for DPC siRNA Delivery System With Peptide Backbone
5/7/2013 11:13:54 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ:ARWR), a targeted therapeutics company, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Number 13/326,433 entitled, “Peptide-Based In Vivo siRNA Delivery System.” The allowed claims specifically protect the use of targeted melittin or melittin-like peptides to facilitate delivery of siRNA conjugates to hepatocytes. This new patent protection covers the composition of the Dynamic Polyconjugate, or DPC, delivery system used in Arrowhead's RNAi-based drug candidate, ARC-520, against chronic hepatitis B virus infection.
Help employers find you! Check out all the jobs and post your resume.
comments powered by